Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 4 de 4
Filtrer
Plus de filtres











Base de données
Gamme d'année
1.
Cancer Res ; 83(2): 251-263, 2023 01 18.
Article de Anglais | MEDLINE | ID: mdl-36354374

RÉSUMÉ

Epithelial ovarian cancer is a highly heterogeneous and malignant female cancer with an overall low survival rate. Mutations in p53 are prevalent in the major ovarian cancer histotype, high-grade serous ovarian carcinoma (HGSOC), while p53 mutations are much less frequent in other ovarian cancer subtypes, particularly in ovarian clear cell carcinoma (OCCC). Advanced stage OCCC with wild-type (WT) p53 has a worse prognosis and increased drug resistance, metastasis, and recurrence than HGSOC. The mechanisms responsible for driving the aggressiveness of WT p53-expressing ovarian cancer remain poorly understood. Here, we found that upregulation of MEX3A, a dual-function protein containing a RING finger domain and an RNA-binding domain, was critical for tumorigenesis in WT p53-expressing ovarian cancer. MEX3A overexpression enhanced the growth and clonogenicity of OCCC cell lines. In contrast, depletion of MEX3A in OCCC cells, as well as ovarian teratocarcinoma cells, reduced cell survival and proliferative ability. MEX3A depletion also inhibited tumor growth and prolonged survival in orthotopic xenograft models. MEX3A depletion did not alter p53 mRNA level but did increase p53 protein stability. MEX3A-mediated p53 protein degradation was crucial to suppress ferroptosis and enhance tumorigenesis. Consistently, p53 knockdown reversed the effects of MEX3A depletion. Together, our observations identified MEX3A as an important oncogenic factor promoting tumorigenesis in ovarian cancer cells expressing WT p53. SIGNIFICANCE: Degradation of p53 mediated by MEX3A drives ovarian cancer growth by circumventing p53 tumor suppressive functions, suggesting targeting MEX3A as a potential strategy for treating of ovarian cancer expressing WT p53.


Sujet(s)
Adénocarcinome à cellules claires , Ferroptose , Tumeurs de l'ovaire , Protéines de liaison à l'ARN , Protéine p53 suppresseur de tumeur , Femelle , Humains , Adénocarcinome à cellules claires/traitement médicamenteux , Carcinogenèse/génétique , Carcinome épithélial de l'ovaire , Lignée cellulaire tumorale , Transformation cellulaire néoplasique/génétique , Transformation cellulaire néoplasique/métabolisme , Ferroptose/génétique , Tumeurs de l'ovaire/génétique , Tumeurs de l'ovaire/métabolisme , Tumeurs de l'ovaire/anatomopathologie , Phosphoprotéines/génétique , Phosphoprotéines/métabolisme , Protéines de liaison à l'ARN/génétique , Protéines de liaison à l'ARN/métabolisme , Protéine p53 suppresseur de tumeur/génétique , Protéine p53 suppresseur de tumeur/métabolisme
2.
Int J Mol Sci ; 22(20)2021 Oct 16.
Article de Anglais | MEDLINE | ID: mdl-34681835

RÉSUMÉ

Paracrine factors of human mesenchymal stem cells (hMSCs) have the potential of preventing adverse cardiac remodeling after myocardial infarction (MI). S100A8 and S100A9 are calcium-binding proteins playing essential roles in the regulation of inflammation and fibrous tissue formation, and they might modulate the paracrine effect of hMSCs. We isolated human amniotic mesenchymal stem cells (hAMSCs) and examined the changes in the expression level of regulatory genes of inflammation and fibrosis after hAMSCs were treated with S100A8/A9. The anti-inflammatory and anti-fibrotic effects of hAMSCs pretreated with S100A8/A9 were shown to be superior to those of hAMSCs without S100A8/A9 pretreatment in the cardiomyocyte hypoxia/reoxygenation experiment. We established a murine myocardial ischemia/reperfusion model to compare the therapeutic effects of the conditioned medium of hAMSCs with or without S100A8/A9 pretreatment. We found the hearts administered with a conditioned medium of hAMSCs with S100A8/A9 pretreatment had better left ventricular systolic function on day 7, 14, and 28 after MI. These results suggest S100A8/A9 enhances the paracrine therapeutic effects of hAMSCs in aspects of anti-inflammation, anti-fibrosis, and cardiac function preservation after MI.


Sujet(s)
Calgranuline A/physiologie , Calgranuline B/physiologie , Immunomodulation , Cellules souches mésenchymateuses/physiologie , Lésion de reperfusion myocardique/métabolisme , Myocytes cardiaques/métabolisme , Animaux , Protéines de liaison au calcium/physiologie , Cellules cultivées , Modèles animaux de maladie humaine , Fibrose/métabolisme , Régulation de l'expression des gènes , Humains , Agents immunomodulateurs/pharmacologie , Inflammation/métabolisme , Ischémie/métabolisme , Mâle , Cellules souches mésenchymateuses/effets des médicaments et des substances chimiques , Souris , Souris de lignée C57BL , Infarctus du myocarde/métabolisme
3.
Taiwan J Obstet Gynecol ; 59(4): 520-526, 2020 Jul.
Article de Anglais | MEDLINE | ID: mdl-32653123

RÉSUMÉ

OBJECTIVE: Bovine mastitis results in economic loss due to decrease in milk production. Antibiotic ointments are commonly used for treating. However, residue and anti-microbial resistance warranted attention progressively. Fortunately, stem cell anti-inflammatory properties and paracrine expression of cytokines accelerates wound healing and suppresses inflammatory reactions in mastitis. The objective of this study is to use the conditioned-Dulbecco's pluripotent stem cells (DPBS) from amniotic membrane stem cells (AMSCs) in treating bovine mastitis. MATERIALS AND METHODS: The cows with mastitis were divided into two groups. In antibiotic control group, the cows were given tetraneomycin ointment. In conditioned-DPBS of AMSCs treatment group, amniotic membrane was collected for AMSCs after delivery. With expression of surface antigen and potential of tri-linage differentiation, AMSCs were injected into mammary glands. Then, milk was sampled every three days to monitor the effect of both treatments. The quality of milk was measured with pH, titratable acidity, free calcium ions and somatic cell count. RESULTS: Our results demonstrated the Bovine AMSCs expressed CD44, low levels of CD4 and no CD105. Bovine AMSCs demonstrated the differentiation capability in the tri-cell lineages. Mastitis treatment with conditioned-DPBS from AMSCs (experimental group) and conventional antibiotics (control group) showed insignificant difference in pH value and titratable acidity. The level of ionic calcium concentration in the conditioned-DPBS group decreased from 3rd day to 12th day, while the level in the antibiotic group decreased from 0 day to 12th day. The somatic cell number was similar in both groups, which meet the standard of Taiwan milk collection. CONCLUSION: In conclusion, conditioned-DPBS from bovine AMSCs has the therapeutic potential to treat bovine mastitis and may replace antibiotics therapy in the future.


Sujet(s)
Mammite bovine/thérapie , Lait/composition chimique , Cellules souches pluripotentes/transplantation , Animaux , Antibactériens/administration et posologie , Antibactériens/effets indésirables , Bovins , Modèles animaux de maladie humaine , Femelle , Humains , Lactation/immunologie , Lactation/métabolisme , Glandes mammaires animales/métabolisme , Onguents/administration et posologie
4.
Asian-Australas J Anim Sci ; 33(9): 1455-1462, 2020 Sep.
Article de Anglais | MEDLINE | ID: mdl-32054212

RÉSUMÉ

OBJECTIVE: The purpose of this study was to investigate whether goose growth and feather characteristics are influenced by their line and feeding surroundings, inclusive of floor materials and types, since there are no reports regarding these factors. METHODS: The 240 White Roman geese which were hatched and sex identified came from 3 commercial goose farms. They were randomly distributed to 24 pens depending on a completely random design. The study continued for 13 weeks and included 3 lines of commercial geese and 2 floor types (cement strip floor [CSF] or cement floor [CF]). RESULTS: The day one gosling weight from A farm was lower than other two farms (96 g vs 107 and 115 g; p<0.001). Afterwards, the body weight, back length, keel length, chest girth and main wing feather length among 3 farms showed no significance difference prior to 12 weeks. The CF group showed heavier body weight, shorter back length, longer keel length, shorter chest girth and shorter main wing feather length than the CSF group prior to 12 weeks. The down weight in the CF was heavier than the CSF group (57.1 g vs 41.8 g; p<0.01) prior to 13 weeks. CONCLUSION: The body weight showed the positive relations for dry feather weight (r = 0.59), down weight (r = 0.69), percent of the down weight of live body weight prior to 13 weeks (r = 0.61).

SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE